• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Nectar Opens First Brick-and-Mortar Allergy Clinic in NYC

by Syed Hamza Sohail 08/29/2023 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

What You Should Know:

  • Nectar Life Sciences, the trusted health technology company behind the first hybrid, vertically-integrated allergy care platform, today announced the grand opening of its flagship Nectar Allergy Center, located in New York City.
  • The clinic expands Nectar’s platform from virtual care offerings to the physical realm, creating a hybrid model that treats both adults and children wherever it’s convenient for them. Nectar’s care offerings are now expanding from environmental allergies to more complex allergic conditions, including asthma, food allergies, and eczema. 

Exploring New Horizons in Allergy Medicine

As part of this launch, the company is significantly bolstering its clinical and scientific expertise by adding new board-certified allergists to the leadership team. Nectar Life Sciences has appointed Dr. Shyam Joshi, M.D., as the company’s first Chief Scientific Officer and hired Dr. Tania Elliott, M.D., as Chief Medical Officer. Dr. Akansha Ganju, M.D., has also joined the company as Medical Director of the Nectar Allergy Center.

Nectar Life Sciences is transforming allergy care with comprehensive, data-driven clinical innovation at a time when allergies are the #1 chronic condition in the U.S. More than 120 million Americans suffer from allergies and related conditions that make their lives difficult and affect their overall health. Nectar’s proprietary research found that 70% of allergy sufferers mask their symptoms with antihistamines and other over-the-counter products that may provide temporary relief but don’t solve the root cause – and 45% have never seen an allergist.

As part of the company’s mission to change those numbers by empowering and educating patients, the Nectar Allergy Center is a 3,250-square-foot facility at 176 3rd Avenue near Manhattan’s Union Square. The clinic took inspiration from the design and experience of inviting hotels and restaurants, rather than traditional medical offices. Increasing accessibility to comprehensive allergy care is a core part of Nectar Life Sciences’s mission, so the Allergy Center is strategically located near many subway and bus stops. The space was thoughtfully designed with modern, hypoallergenic decor to maximize efficiency, safety and functionality while accommodating a comfortable relationship between providers and patients. The clinic features a fully digital check-in, examination rooms set up for shared decision-making with educational flatscreens for patients, and relaxing observation areas where patients can catch up on work during longer treatments. 

“As a native New Yorker who was born and raised in Washington Heights, where I suffered from severe allergies for decades, I’m extremely proud to establish our first Nectar Allergy Center in my hometown,” said Dr. Kenneth Chahine, Ph.D., J.D., Co-Founder & CEO of Nectar Life Sciences. “Opening this clinic represents a significant milestone in our mission to make transformative allergy care more accessible to the community, using the power of science and technology. Many New Yorkers are dreading the fall allergy season that’s just around the corner, as 90% of people with allergies have stayed home from work, school or other activities due to their symptoms. Our team is eager to provide comfort and help patients improve their quality of life, so they don’t have to miss out on the moments that truly matter.”

The center’s offerings expand upon Nectar’s at-home allergy testing and treatment solutions, which launched in February to detect and treat up to 40 indoor and outdoor allergies, with test sales growing by 50% each month since then. Nectar is the first allergy care platform with a vertically-integrated business model that allows the company to maintain quality control throughout the entire patient journey. In addition to the new clinic, the integrated ecosystem includes a compounding pharmacy, CLIA-certified and CAP-accredited lab testing facility, and telehealth network of allergists. Nectar’s proprietary offering, Nectar Allergy Drops, is an evidence-based, safe, and cost-effective treatment that provides lifelong relief from allergies by treating the root cause with sublingual immunotherapy drops that are administered under the tongue. Nectar’s team of seasoned healthcare executives and innovators developed a unique, patent-pending protocol using FDA-approved single allergens to create Allergy Drops that are customized to each patient and treat multiple allergies simultaneously. As a result, survey data shows a vast majority of patients report experiencing improvement in allergy symptoms within a few months of starting Nectar.

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Paradigm Shift in Diabetes Care with Studio Clinics: Q&A with Reach7 Founder Chun Yong

Most-Read

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

The Evolving Role of Physician Advisors: Bridging the Gap Between Clinicians and Administrators

The Evolving Physician Advisor: From UM to Value-Based Care & AI

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

2019 MedTech Breakthrough Award Category Winners Announced

MedTech Breakthrough Announces 2025 MedTech Breakthrough Award Winners

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |